All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
ZUMA-12: 3-year follow-up analysis of axi-cel in high-risk large B-cell lymphoma
Bookmark this article
|
The primary analysis of the ZUMA-12 trial (NCT03761056) showed that axi-cel achieved a CRR of 78% in patients with high-risk LBCL (N = 37), with no new safety signals observed.1 Results from the 3-year follow-up analysis of the trial evaluating the long-term efficacy and safety of axi-cel in patients with high-risk LBCL were published by Chavel et al.1 in Blood Advances. The primary endpoint was investigator-assessed CRR. Key secondary endpoints included DOR, EFS, PFS, OS, and safety.1 |
| Key learnings |
| After a median follow-up of 47.0 months, the CRR and ORR were 86% (95% CI, 71–95) and 92%, respectively, among evaluable patients (n = 37). In patients with double- or triple-hit lymphoma with IPI ≤2 (n = 5), the CRR was 83%. |
| The median DOR was not reached, and the 36-month ongoing response rate was 81.8% (95% CI, 63.9–91.4). The 36-month estimated EFS, PFS, and OS rates were 73.0% (95% CI, 55.6–84.4), 75.1% (95% CI, 57.5–86.2), and 81.1% (95% CI, 64.4–90.5), respectively. |
| No new safety signals were reported. Malignancies were reported in four patients, none of which were related to axi-cel. Deaths were reported in eight patients due to disease progression (n = 5), NRM (n = 2), and sepsis (n = 1). |
| These findings show the potential of axi-cel as an effective first-line therapy for patients with high-risk LBCL, with high and durable response rates and a manageable safety profile. The phase III ZUMA-23 trial (NCT05605899) is currently recruiting and will evaluate axi-cel vs SOC. |
Abbreviations: axi-cel, axicabtagene ciloleucel; CI, confidence interval; CRR, complete response rate; DOR, duration of response; EFS, event-free survival; IPI, International Prognostic Index; LBCL, large B-cell lymphoma; NRM, non-relapse mortality; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SOC, standard of care.
- Chavez JC, Dickinson M, Munoz J, et al. Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12). Blood. 2025. Online ahead of print. DOI: 10.1182/blood.2024027347
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
7 votes - 18 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox